Alerts will be sent to your verified email
Verify EmailLINCOLN
|
Lincoln Pharma
|
Syncom Formulations
|
Jagsonpal Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
8.98 % | n/a | n/a |
|
R&D as a % of Total Sales
|
1.88 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
15.1 % | 9.79 % | 16.01 % |
|
5yr average Equity Multiplier
|
1.26 | 1.41 | 1.27 |
|
5yr Average Asset Turnover Ratio
|
0.82 | 0.81 | 1.09 |
|
5yr Avg Net Profit Margin
|
14.59 % | 8.78 % | 12.08 % |
|
Price to Book
|
1.66 | 3.15 | 5.31 |
|
P/E
|
14.35 | 17.09 | 34.04 |
|
5yr Avg Cash Conversion Cycle
|
-6.41 Days | 61.57 Days | 2.39 Days |
|
Inventory Days
|
43.91 Days | 27.32 Days | 31.56 Days |
|
Days Receivable
|
91.75 Days | 82.75 Days | 15.63 Days |
|
Days Payable
|
128.38 Days | 79.41 Days | 59.94 Days |
|
5yr Average Interest Coverage Ratio
|
63.13 | 31.44 | 66.99 |
|
5yr Avg ROCE
|
19.81 % | 13.63 % | 18.99 % |
|
5yr Avg Operating Profit Margin
|
18.35 % | 9.97 % | 13.23 % |
|
5 yr average Debt to Equity
|
0.0 | 0.19 | 0.01 |
|
5yr CAGR Net Profit
|
5.76 % | 36.24 % | 26.54 % |
|
5yr Average Return on Assets
|
11.92 % | 7.11 % | 12.71 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
49.78 % | 50.57 % | 67.89 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
2.78 % | 0.0 | -0.82 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Lincoln Pharma
|
Syncom Formulations
|
Jagsonpal Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|